About Us

We believe in this technology and its ability to have a truly positive impact in Oncology.
OncoSil™ For Healthcare Professionals

Our Mission

OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes for people living with cancer by utilising selective and targeted intratumoral placement of Phosphorous 32 (32P) Microparticles.

OncoSil™ is our brachytherapy device.  Its targeted approach enables health care professionals to deliver a greater radiation dose directly into the tumour, while sparing surrounding critical organs2.

We believe in this technology and its ability to have a truly positive impact in Oncology.

 

Our Approvals

We operate from 2 locations globally with access to 11 global markets via direct sales and distributors and operates facilities in Germany.

Global Headquarters

Global Headquarters
OncoSil Medical Ltd.
Level 5, 7 Eden Park Drive
Macquarie Park,
NSW, 2113

European Office

OncoSil Medical Europe GmbH
Kurfuerstendamm 195/3rd Fl.
10707 Berlin

Learn more about our achievements and the people behind them.

Our People
Our History
References:
1. OncoSil™ is intended for intratumoural implantation into a pancreatic tumour via injection under endoscopic ultrasound guidance. OncoSil™ is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine based chemotherapy.
2. Skowronek J. J Contemp Brachytherapy 2017; 9: 581-589.
3. PanCO ClinicalTrials.gov Identifier: NCT03003078
4. OncoPaC-1 ClinicalTrials.gov Identifier: NCT03076216
5. PanCO Publication